Addressing Treatment Gaps in HER2+ MBC
Unmet needs regarding the selection and sequencing of therapies for patients with HER2-positive metastatic breast cancer.
Read More
Optimizing Therapy in HER2+ MBC Across the Globe
A global perspective on managing patients with HER2-positive metastatic breast cancer through multiple lines of therapy based on treatment advances.
Read More
Therapeutic Sequencing in HER2+ MBC
A global perspective pertaining to how to best sequence therapies used to treat HER2+ metastatic breast cancer based on treatment advances and data presented on at ESMO 2021.
Read More
Updates to HER2CLIMB in HER2+ MBC
Breast oncologists react to updated overall survival data, progression-free survival data, and quality-of-life data from the HER2CLIMB study of tucatinib for HER2+ metastatic breast cancer, as well as consider using the drug in combination with other novel therapies.
Read More
Managing TRAEs Associated With Novel HER2+ MBC Therapies
Recommendations for monitoring for and managing adverse events associated with newer therapies being sequenced into HER2+ metastatic breast cancer treatment algorithms.
Read More
Standard Treatment Approaches in HER2+ MBC
A global perspective regarding standards of care for treating HER2-positive metastatic breast cancer in earlier treatment settings.
Read More
Breast oncologists from across the globe react to incidence rates of HER2-positive metastatic breast cancer as they relate to rates of progression to brain metastases and treatment advances.
Read More
HER2+ Breast Cancer: Key Takeaways From HER2CLIMB
September 8th 2021An overview of the latest data demonstrated by the HER2CLIMB study evaluating the efficacy and safety of tucatinib in combination with capecitabine and trastuzumab for patients with relapsed/refractory metastatic HER2-positive breast cancer.
Read More
Standard of Care for R/R Metastatic HER2+ Breast Cancer
September 8th 2021Current treatment options and outcomes for patients with metastatic HER2-positive breast cancer who progress on HER2-targeted therapy, with special insight regarding the management of brain metastasis and visceral disease.
Read More